Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMDX
Strong SellSinkerInsight Molecular Diagnostics Inc. · Healthcare · United States · $135M · Avg Vol: $763K/d
3
StockRankGet insider-trade alerts
Q
15
V
23
M
27
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
COMPANY DESCRIPTION
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0M | 1.5M | 1.9M | 4.1M | 61.8% | 1.7M | 1.0M | 6.7M | 28.2% |
| EPS | -3.67 | -0.96 | -4.66 | -1.65 | — | -1.52 | -0.93 | -0.80 | — |
| Shares | 32.3M | 32.3M | 17.5M | 28.7M | -11.2% | 32.7M | — | — | — |
| Debt | 3.5M | 2.9M | 3.7M | 3.5M | -0.4% | 2.6M | — | — | — |
| Equity | 34.3M | 20.5M | -12.3M | -31.5M | -40.3% | — | — | — | — |
| Op CF | -45.6M | -23.3M | -20.7M | -22.2M | — | -27.1M | — | — | — |
| Inv CF | -4.3M | -0.9M | -0.5M | -3.2M | — | — | — | — | — |
| Fin CF | 35.8M | 12.2M | 20.4M | 28.1M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-13.5%
SMA 50SMA 200
Close
$3.98
RSI (14)
39.3
52W High
$8.51
From 52W High
0.5%
SCORE BREAKDOWN
Quality
15
ROIC
-348.9%1.4
ROE
—N/A
GP/Assets
3.2%15.7
Op. Margin
-3815.1%4.0
FCF/Assets
-106.7%1.8
Piotroski
430.8
Int. Cover
-50.0x5.8
D/E Ratio
—N/A
Current Ratio
2.00x38.9
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-3.5x25.0
P/FCF
—N/A
P/B
-6.3x25.0
P/S
80.9x7.4
Div Yield
—N/A
Momentum
27
52W High %
47%20.5
RS 6M
-37%22.3
SMA 50/200
0.88x27.4
EPS Rev 4W
-2.6%18.3
EPS Rev 12W
—N/A
EPS Improve
+47%52.9
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$135M
P/E (Forward)
-5.2x
Gross Margin
48.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMDX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMDX | Insight Molecular Diagnostics Inc.(you) | $135M | 3 | Strong Sell |
| 950130.KQ | Access Bio, Inc. | $65M | 13 | Strong Sell |
| XGN | Exagen Inc. | $179M | 28 | Sell |
| MYGN | Myriad Genetics, Inc. | $302M | 21 | Sell |
| BDSX | Biodesix, Inc. | $283M | 29 | Sell |
| 950200.KQ | Psomagen, Inc. | $50M | 24 | Sell |
| PRPO | Precipio, Inc. | $52M | 47 | Hold |
| FRNM | Freenome, Inc. | $1.6B | 18 | Strong Sell |
| FLGT | Fulgent Genetics, Inc. | $540M | 45 | Hold |
| PSNL | Personalis, Inc. | $1.8B | 24 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%